dsm265

Small moleculeexperimental

Clinical trial activity

7 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Feb 1, 2015 (NCT02389348)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • dsm265
  • dsm265

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03637517Phase 1Oct 31, 2018AbbVie, Medicines for Malaria Venture
NCT02750384Phase 1May 1, 2016AbbVie, Medicines for Malaria Venture
NCT02562872Phase 1Mar 1, 2016Department of Defense, Medicines for Malaria Venture, University of Washington
NCT02123290Phase 2Jan 1, 2016Asociación Civil Selva Amazónica, Medicines for Malaria Venture
NCT02573857Phase 1/Phase 2 (Phase 2)Oct 1, 2015Clinical Neuroscience Solutions, Inc., Medicines for Malaria Venture, Q-Pharm, University of Queensland
NCT02450578Phase 1Oct 1, 2015Medicines for Malaria Venture, University of Tuebingen
NCT02389348Phase 1/Phase 2 (Phase 2)Feb 1, 2015Clinical Neuroscience Solutions, Inc., Medicines for Malaria Venture, Q-Pharm, University of Queensland
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Medicines for Malaria VentureAcademic/Hospital7722015
AbbVieFor profit2012016
Clinical Neuroscience Solutions, Inc.For profit2012015
Q-PharmFor profit2012015
University of QueenslandAcademic/Hospital2012015
Asociación Civil Selva AmazónicaAcademic/Hospital1012016
Department of DefenseGovernment1012016
University of TuebingenAcademic/Hospital1012015
University of WashingtonAcademic/Hospital1012016
9 organizations
Page 1 / 1